Outlook Therapeutics up 49% on advancement of ONS-5010 [Seeking Alpha]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Outlook Therapeutics up 49% on advancement of ONS-5010 Thinly traded nano cap Outlook Therapeutics ( OTLK +49.3% sign-off The three studies are: NORSE 4, in patients with branch retinal vein occlusion (BRVO) and NORSE 5 & 6 in diabetic macular edema patients. All should launch in 2020 after enrollment is completed in NORSE 2
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdateGlobeNewswire
- Outlook Therapeutics® Streamlines OperationsGlobeNewswire
- Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDGlobeNewswire
- Outlook Therapeutics® Announces Executive Leadership Transition [Yahoo! Finance]Yahoo! Finance
OTLK
Earnings
- 8/14/24 - Beat
OTLK
Sec Filings
- 12/27/24 - Form 8-K
- 12/16/24 - Form 8-K
- 12/4/24 - Form 8-K
- OTLK's page on the SEC website